(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

"MediWound commences Phase III trial for venous leg ulcers treatment" was originally created and published by Clinical Trials ...

About Venous Leg Ulcers 1 EscharEx ® is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in the advanced stages of clinical development ...

MediWound (MDWD) stock rises 4% as it begins Phase 3 trials for EscharEx treating venous leg ulcers, with FDA submission plans and mid-2026 interim ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.

The Department’s action is particularly good news for Medicare beneficiaries suffering from diabetic foot ulcers and venous leg ulcers ... for lengthy in-hospital treatment, as well as premature ...

Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) is projected to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect Tactile Systems Technology to ...